The February 2019 MYnd Analytics deck serves as a strategic roadmap for a company at a major corporate crossroads. Trading on the NASDAQ under the symbol MYND, the company positions itself as a dual-threat in behavioral health, combining a proprietary AI/Machine Learning platform (PEER) with a growing telemedicine arm. The deck highlights a significant clinical database of over 11,000 patients and 40,000 outcomes to validate its predictive capabilities. However, the primary purpose of this specific presentation is to socialize a complex transaction: a merger with Emmaus Life Sciences followed…
Key takeaways
- The company identifies a massive market gap where two out of three individuals with mental illness never seek care, and millions fail to respond to initial therapies (Slide 4).
- MYnd utilizes a Psychiatric Electroencephalographic Evaluation Registry (PEER) containing data from 11,000+ patients and 40,000+ outcomes (Slide 10).
- Clinical results claim a 144% improvement in depression scores and a 75% reduction in suicidality through their personalized treatment plans (Slide 10).
- The business model relies heavily on expanding payor coverage, citing the Federal Mental Health Parity Act and the 21st Century Cures Act as tailwinds (Slide 7).
- Strategic growth for 2019 is centered on partnerships with Sanford Health and penetrating the Canadian military and U.S. VA systems (Slide 16).
- The deck outlines a reverse-merger style transaction where Emmaus shareholders will own 94% of the post-merger MYnd Analytics stock (Slide 19).
- A planned spinoff ensures current MYnd shareholders retain 100% ownership of the predictive analytics and telemedicine business as a new standalone company (Slide 19).
- The deck omits a traditional 'Team' slide and detailed financial projections, focusing instead on clinical testimonials and corporate structure (Slides 13, 19).
MYnd Analytics: A Public Market Strategic Pivot
The February 2019 investor presentation for MYnd Analytics (NASDAQ: MYND) is not a typical venture capital pitch deck. Because the company was already publicly traded at the time of this presentation, the deck functions as a communication tool for shareholders to understand a complex corporate restructuring. The narrative moves from clinical validation to market tailwinds, culminating in the explanation of a merger and spinoff. The following teardown examines the seven provided slides to understand how the company positioned its technology and its future.
Slide 1: Title and Positioning
The cover slide establishes MYnd Analytics as a 'behavioral health company.' It immediately identifies two value propositions: improving access to care and reducing 'trial and error prescribing.' By including the NASDAQ ticker (MYND) prominently, the company signals its maturity and regulatory compliance. The subtitle 'Improving Outcomes and Lowering Costs' targets the two primary concerns of healthcare payors, setting the stage for a B2B-focused value proposition.
Slide 4: The Core Problem and Solution Intersection
Slide 4 uses a Venn diagram to show the intersection of 'Data Analytics/Machine Learning' and 'Telemedicine.' This is a classic positioning move to show that the company isn't just a service provider (telemedicine) or just a software provider (AI), but a hybrid that solves a specific bottleneck. The slide notes that 'Two out of three individuals with mental illness never seek medical care,' and 'millions fail to respond to current medication therapies.' By placing their logo at the center of these two circles, MYnd claims to solve both the access problem (via telemedicine) and the efficacy problem (via analytics).
Slide 7: Regulatory and Reimbursement Tailwinds
For any healthcare technology company, the 'How do we get paid?' question is paramount. Slide 7 addresses this by listing a decade of legislative progress, from the Federal Mental Health Parity Act of 2008 to the 21st Century Cures Act of 2016. The slide explicitly mentions that 'CPT codes exist for reimbursement.' This is a critical de-risking slide for investors; it suggests that the company is not fighting for new laws to be passed but is instead 'strategically positioned' to capture existing, expanding budgets. The inclusion of a Piper Jaffray quote regarding the doubling of telemedicine adoption adds third-party validation to their growth thesis.
Slide 10: The PEER AI Platform
This is the 'Product' slide. It introduces the Psychiatric Electroencephalographic Evaluation Registry (PEER). The slide defines the technology as using EEG—a 'painless, non-invasive test'—to record brain activity. The most compelling figure here is the scale of their data: '11,000+ patients & 40,000+ outcomes.' In the world of AI and machine learning, the size of the training set is the moat. The slide claims specific clinical outcomes: a 144% improvement in depression scores and a 75% reduction in suicidality. These are bold claims that, if verified, position the product as a life-saving clinical tool rather than a wellness app.
Slide 13: Clinical Social Proof
Slide 13, titled 'What Doctors Say,' serves as a testimonial page. It features quotes from high-level medical professionals, including the Chief of Clinical Pathology at Quest Diagnostics and a psychiatrist from Stanford University School of Medicine. The quotes focus on the shift from subjective 'clinical judgment' to 'objective office procedures.' This slide is designed to overcome the natural skepticism of the medical community toward 'black box' AI solutions by showing that respected peers already endorse the methodology.
Slide 16: 2019 Milestones and Growth Strategy
The roadmap slide lists five key milestones. The strategy is clearly focused on institutional partnerships rather than direct-to-consumer marketing. Mentioning 'Sanford Health,' 'Canadian military trial,' and 'penetrating the VA' indicates a focus on large, stable contracts. The fifth milestone lists a wide variety of facilities, from 'correctional facilities' to 'nursing homes,' suggesting that the company views its telemedicine arm as a horizontal service that can be plugged into any institutional setting where behavioral health is currently underserved.
Slide 19: The Emmaus Merger and Spinoff
This is the most complex slide in the deck and represents the primary 'Ask' or 'Update' for the investor. It details a merger with Emmaus Life Sciences where Emmaus shareholders will eventually own 94% of the combined company. To a casual observer, this looks like a total acquisition of MYnd. However, the final bullet point clarifies the 'Spinoff': MYnd shareholders will continue to own 100% of the 'predictive analytics and telemedicine business' as a new standalone public company. This maneuver is often used to allow a private company (Emmaus) to go public via a reverse merger while allowing the original company's assets to remain independent. It is a sophisticated financial play that requires clear communication to prevent shareholder panic.
What Works in This Deck
Data-Backed Moat: Citing 40,000+ outcomes (Slide 10) provides a sense of scale that is difficult for new startups to replicate. · Regulatory Alignment: Slide 7 does an excellent job of showing that the company is swimming with the current of federal law and reimbursement trends. · High-Stakes Outcomes: By focusing on suicidality and depression scores (Slide 10), the company elevates its mission from 'efficiency' to 'life-saving,' which carries more weight in healthcare investing. · Clear Corporate Action: Despite the complexity of the Emmaus deal, Slide 19 breaks down the ownership percentages and the spinoff plan in a way that is legally precise yet readable.
What is Missing
Financial Performance: As a public company, one would expect to see historical revenue, burn rate, or at least a summary of the balance sheet. These are entirely absent from the provided slides. · Competitive Landscape: The deck operates as if MYnd is the only player in the space. There is no mention of other EEG-based diagnostic tools or the dozens of telemedicine competitors that were emerging in 2019. · The Team: There is no slide introducing the management team or the board of directors. While the 'What Doctors Say' slide provides clinical credibility, it doesn't tell the investor who is actually running the business operations. · Unit Economics: There is no explanation of the cost to acquire a patient or the lifetime value of a contract. The deck focuses on 'partnerships' but doesn't explain the margin profile of those partnerships.
Founder Lessons
Use 'Social Proof' for Complex Tech: If your product relies on complex AI or medical science that an investor might not understand, don't just explain the math. Use testimonials from recognized authorities (like the Quest Diagnostics and Stanford MDs on Slide 13) to bridge the trust gap.
Quantify the 'Training Set': If you are building a machine learning company, your most important metric might not be revenue—it might be the size of your proprietary database. MYnd’s mention of 40,000 outcomes (Slide 10) is their strongest competitive moat.
Align with Reimbursement: In HealthTech, the 'user' is rarely the 'payor.' This deck succeeds by showing exactly which laws and CPT codes (Slide 7) make their product a viable business. Founders should always map their product to the existing money flow in their industry.
Structure Complex Deals Simply: If your company is undergoing a merger, pivot, or spinoff, use a dedicated slide with clear bullet points (like Slide 19) to explain who will own what. Ambiguity during corporate transitions is a deal-killer.
Frequently asked questions
- What is the PEER Online platform mentioned in the deck?
- PEER stands for Psychiatric Electroencephalographic Evaluation Registry. According to slide 10, it is a database that uses EEG tests—which record brain electrical activity—combined with machine learning to identify 'endophenotypic markers' of drug response. The goal is to provide physicians with a personalized treatment plan for patients, moving away from the standard trial-and-error method of prescribing behavioral health medications.
- How does MYnd Analytics generate revenue based on these slides?
- The deck does not provide a specific per-unit price or subscription cost. However, slide 7 indicates the revenue model is tied to 'Expanding coverage' and the 'Collaborative Care Model (CoCM).' It mentions that CPT codes exist for reimbursement and that Medicare now provides coverage for 'Psychiatric Collaborative Care Management Services,' suggesting a B2B2C model where they bill through existing healthcare reimbursement frameworks.
- What is the significance of the Emmaus Life Sciences merger?
- As detailed on slide 19, the merger is a structural corporate action. Emmaus Life Sciences, a leader in sickle cell disease treatment, will become a subsidiary of MYnd. In exchange, Emmaus shareholders will receive enough stock to own 94% of the combined entity. Crucially, MYnd plans to spin off its original analytics and telemedicine assets into a new standalone public company, effectively separating the two business lines while maintaining shareholder value.
- What clinical evidence does the company provide for its technology?
- Slide 10 cites 'proven results' including a 144% improvement in depression scores and a 75% reduction in suicidality. The company also leverages social proof on slide 13, featuring testimonials from the Chief of Clinical Pathology at Quest Diagnostics and a retired U.S. Army Colonel, both of whom emphasize the need for objective brain measurement to guide medication choices.
- Who are the primary target customers for MYnd's services?
- Slide 16 outlines a broad target market including outpatient primary care practices (via Sanford Health), schools, universities, nursing homes, correctional facilities, and government entities like the VA and the Canadian military. They are positioning their telemedicine and PEER reports as a tool for any large-scale health system or 'payor' seeking to reduce healthcare costs and improve clinical outcomes.
